Key Takeaways:
The law firm Pomerantz LLP announced an investigation into Replimune Group, Inc. (NASDAQ: REPL) after the company’s stock price collapsed by over 64 percent earlier in the month.
The investigation, announced on April 28, 2026, concerns whether Replimune and certain of its officers or directors engaged in securities fraud or other unlawful business practices, according to a statement from the firm. Investors who purchased stock are advised to contact Danielle Peyton at Pomerantz.
The probe follows a steep decline in Replimune’s stock value. On April 13, 2026, the company’s shares fell $3.06, or 64.26 percent, to close at $1.70. The sell-off erased significant market capitalization and prompted the legal inquiry.
The drop was triggered by an April 10 press release where Replimune announced it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration. The CRL pertained to the Biologics License Application (BLA) for its lead candidate, RP1, intended for treating advanced melanoma.
Replimune’s application for RP1 was for its use in combination with nivolumab. In the announcement, the company disclosed a disagreement with the FDA regarding the sufficiency of the data package submitted to support the BLA. The agency’s CRL indicated that the data was not sufficient for approval, a major setback for the clinical-stage biotechnology company.
Pomerantz LLP, a firm specializing in corporate, securities, and antitrust class-action litigation, is now examining whether the company made misleading statements to investors regarding the drug's approval prospects and the data supporting its application. The firm has offices in New York, Chicago, Los Angeles, and other major cities.
The investigation introduces significant legal and financial risk for Replimune, potentially leading to a class-action lawsuit that could result in substantial damages. For investors, the key upcoming catalyst will be any announcements from the company regarding its plan to address the FDA's concerns and the timeline for a potential resubmission of the BLA for RP1.
This article is for informational purposes only and does not constitute investment advice.
